BridgeBio Q4 revenue jumps on Attruby sales

BridgeBio Pharma

24/02/2026 21:09

Overview

Biopharmaceutical company's Q4 revenue rose significantly, driven by Attruby product sales

Company reported positive Phase 3 trial results for multiple drugs

Company issued $632.5 mln convertible notes to fund operations

Outlook

BridgeBio plans NDA submission for BBP-418 in 1H 2026, U.S. launch late 2026/early 2027

Company expects NDA submission for encaleret in 1H 2026, U.S. launch late 2026/early 2027

BridgeBio anticipates NDA submission for infigratinib in 2H 2026, launch early to mid 2027

Result Drivers

ATTRUBY SALES - Attruby net product revenue increased by 35% quarter-over-quarter, driven by its differentiated profile and continued prescribing growth

FINANCIAL POSITION - Issuance of $632.5 mln convertible notes in January 2026 to fund planned commercial and pipeline operations

Company press release: ID:nGNX8qbj9j

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$194.64 mln
Q4 Operating Income
-$139.56 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for BridgeBio Pharma Inc is $96.00, about 41.4% above its February 23 closing price of $67.91

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)